CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 679 enrolled
Drug / intervention
albendazole BENDEX +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02420574
NCT02420574N/ACompleted

Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia

University Ghent·interventional·Posted Apr 20, 2015·Updated Dec 9, 2022

In Brief

A clinical study evaluating albendazole BENDEX and albendazole OVIS for Helminthiasis. Completed, enrolled 679 participants.

Detailed Summary

Infections with soil-transmitted helminthes (STH) occur throughout the developing world and remain a major public health problem in the poorest communities. Preventive chemotherapy (PC) programs in which single-dose albendazole 400 mg or single-dose mebendazole 500 mg - the drugs of choice for STH - are administered at the population level, is the main strategy for STH control. To ensure quality, these drugs are being widely donated by GlaxoSmithKline (GSK) (albendazole (ALB), Zentel) and Johnson \& Johnson (mebendazole (MEB), Vermox). In addition to this, there are a wide variety of ALB and MEB tablets available on the local market. Although little is known about the quality of anthelmintics sold for human use, several publications have reported variability in the quality of generic anthelmintics used in veterinary medicine. The main objective of the present study is to compare the efficacy of two ALB brands bought on the local market, including OVIS (Korea, DAEHWA pharmaceutical) and BENDEX (India, Cipla)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHelminthiasis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 20, 2015
Enrollment StartFeb 1, 2014
Primary CompletionApr 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.2 years ago

Interventions

albendazole BENDEXdrug

randomized clinical trial with 2 parallel arms

albendazole OVISdrug